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ABSTRACT
 
Breast cancer is the most frequent cancer among Swedish women and in 2012, 8490 new inva-
sive breast cancers were diagnosed. The incidence of in situ breast cancer has markedly in-
creased since nationwide mammography screening was introduced in the late 1980s. The in-
creasing figures of in situ breast cancer are predominantly attributable to an increased frequency 
of ductal carcinoma in situ (DCIS). In 2012, 1443 in situ breast cancers were diagnosed in Swe-
den, which is approximately 15% of all diagnosed breast cancers.  
 
The main aims of the first two papers were to study the long-term HRQOL after different types 
of surgical treatment in women with DCIS (paper I) and to study the risk of developing a new in 
situ or invasive breast cancer after a first in situ cancer in women with and without a family his-
tory for breast cancer (paper II). Since the 1980s, breast-conserving surgery for DCIS has been 
recommended whenever feasible. Several randomised trials have shown a decreased rate of ipsi-
lateral DCIS or invasive breast cancer recurrence through the addition of adjuvant radiotherapy.  
Mastectomy is still recommended for women with either multifocal DCIS, and/or unfavourable 
proportion between tumour size and breast volume. For these women an immediate breast re-
construction (IBR) is an alternative to maintain a breast contour. As surgery is the primary 
treatment for this disease, it is essential to increase current understanding of its long-term con-
sequences. In paper I, 162 women treated for DCIS with breast-conserving surgery with or 
without postoperative radiotherapy, or with mastectomy and IBR, had a satisfactory long-term 
HRQOL. However, body image appeared to be affected in women after mastectomy and IBR.  
 
Using the population-based Swedish Multi-Generation and Cancer Registers we identified 
8,111 women (paper II) diagnosed with in situ breast cancer between 1980 and 2004. The risk 
of a subsequent invasive breast cancer was increased more than fourfold [SIR 4.55 (95% CI 
4.23- 4.88)] among women with in situ breast cancer as compared to women in the general 
population and the risk for a contralateral in situ breast cancer was almost sixteenfold  increased 
[SIR 15.98(95% CI, 13.23-19.14)]. Having a family history for breast cancer increased the risk 
for contralateral invasive breast cancer by almost 50 % [incidence rate ratio 1.47 (95% CI 1.05-
2.05)]. The risk for a subsequent invasive breast cancer, as well as mortality was substantially 
higher in younger women, which should be taken into account when planning their treatment 
and follow-up. 
 
The main aims of paper III and IV were to evaluate the impact of axillary surgery on arm lym-
phoedema and long-term HRQOL. Axillary lymph node dissection (ALND) was the standard 
surgical procedure for staging well into the 1990s, when it was replaced by the sentinel lymph 
node biopsy (SLNB), in patients with preoperatively no signs of axillary metastases. In a multi-
centre study, including 557 women, we showed that SLNB alone is associated with a minimal 
risk of increased arm volume and few self-perceived symptoms of arm lymphoedema, signifi-
cantly less than after ALND, regardless of lymph node status. Yet, 20% of the women who un-
derwent SLNB, reported symptoms of arm lymphoedema, which emphasizes the importance of 
performing SLNB strictly on patients who can benefit from the staging results.  Three years 
after surgery women in all three study groups appeared to have a satisfactory HRQOL. Women 
reporting self-perceived arm lymphoedema, regardless of objective lymphoedema or not, re-
ported  poorer HRQOL than those women who did not, indicating that more attention should be 
given to the subjective reports of symptoms, in order to better help these women. 
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THESIS AT A GLANCE
 
 
 Aim Subjects and Methods Results and Conclusion 
I 
To investigate and compare long-
term HRQOL, body image, and 
emotional reactions in women 
with in situ breast cancer treated 
with different surgical methods. 
 
Women in Stockholm Coun-
ty with  DCIS  N=162 
 
HRQOL assessed with Ques-
tionnaires: 
SF-36, Hospital and Anxiety 
Scale  and Body Image Scale 
Women treated for DCIS have a satis-
factory long-term HRQOL.  
 
Body image appears to be affected in 
women treated with mastectomy and 
immediate breast reconstruction. 
II 
To evaluate long-term risk of 
subsequent breast cancer and 
mortality in women diagnosed 
with in situ breast cancer. 
To evaluate the impact of family 
history on long-term risk of sub-
sequent breast cancer and mortal-
ity in women diagnosed with in 
situ breast cancer.  
 
All women in the Multi-
Generation Register with first 
in situ breast cancer diag-
nosed  1980-2004   N=8111 
 
Relative risk for second 
breast cancer and relative 
mortality risk in women with 
in situ breast cancer. 
  
 
The risk for a subsequent invasive breast 
cancer, as well as mortality is substan-
tially higher in younger women, which 
should be taken into account when 
planning their treatment and follow-up. 
 
For women with in situ breast cancer a 
positive family history increases the risk 
only for a contralateral invasive breast 
cancer. 
III 
To compare arm lymphoedema 
after SLNB alone vs. ALND, 
both in node-negative and node-
positive breast cancer patients.  
To examine the potential associa-
tion between subjectively and 
objectively measured arm lym-
phoedema.  
Women operated for invasive 
breast cancer in four  
hospitals in Sweden.    
N=557  
 
Arm lymphoedema measured 
with water displacement 
technique. 
 
Questionnaire regarding self-
perceived symptoms of arm 
lymphoedema. 
SLNB is associated with a minimal risk 
of increased arm volume and few self-
perceived symptoms of arm lymphoe-
dema. Yet, 20% of women report symp-
toms of arm lymphoedema after sentinel 
lymph node biopsy, which emphasizes 
the importance of performing axillary 
surgery strictly on patients who can 
benefit from the staging results.   
 
Three years after surgery there is a weak 
correlation between objectively meas-
ured arm lymphoedema and self-
perceived symptoms of arm lymphoe-
dema.  
 
IV 
To compare long-term HRQOL 
in patients undergoing SLNB 
alone vs. ALND with or without 
axillary metastases.  
To assess the impact of objective 
arm lymphoedema and subjective 
ratings on health-related quality 
of life  
 
Women operated for invasive 
breast cancer in four hospit-
als in Sweden.    N=557  
 
HRQOL assessed with SF-36 
questionnaire. 
 
Questionnaire regarding self-
perceived symptoms of arm 
lymphoedema. 
Women treated for invasive breast   
cancer have a satisfactory long-term 
HRQOL.  
Women reporting self-perceived arm 
lymphoedema, regardless of objective 
lymphoedema or not, reported poorer 
HRQOL than those who did not, indi-
cating that more attention should be 
given to the subjective reports of symp-
toms in order to better help these wom-
en. 
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“Where there is love for mankind, there is the love for 
the art of healing”.  
 
Hippocrates  
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BACKGROUND
 
 
 
Epidemiology and risk factors 
In Sweden, breast cancer is the most frequent 
cancer among women, accounting for almost 
30% of all female malignancies
1
. Breast can-
cer incidence and mortality demonstrate a 
distinct geographic variability, with high rates 
in Northern Europe and North America, in-
termediate rates in Southern Europe and Latin 
America and low rates in Asia and Africa
2
. In 
high incidence countries like Sweden, ap-
proximately every tenth to eight woman will 
be afflicted by breast cancer
1, 2
. In 2012, 8490 
new invasive breast cancers were diagnosed 
in Sweden
1
. The incidence of breast cancer 
has increased markedly over time, and in the 
last two decades this increase has been ob-
served in almost all countries
3, 4
. In Sweden, 
the incidence more than  doubled between 
1980 and 2013
5
. The introduction of popula-
tion-based mammography screening have had 
a major influence on the increased incidence, 
but cannot fully explain it
3, 4
. Other factors 
that may have contributed are changes in risk 
factors, e.g. lower parity, increased use of 
hormone replacement therapy, higher age at 
first childbirth and higher mean weight
6
.  
 
The incidence of in situ breast cancer has 
markedly increased since nationwide mam-
mography screening was introduced in Swe-
den in the late 1980s
1
. The increasing figures 
of in situ breast cancer are predominantly 
attributable to an increased frequency of duc-
tal carcinoma in situ (DCIS). Today, the ma-
jority of all DCIS are screening detected
7, 8
. 
In 2012, 1443 in situ breast cancers were di-
agnosed in Sweden, which is approximately 
15% of all diagnosed breast cancers.  This 
compares with 30-50 cases of in situ breast 
cancer per year in the 1960s
9
.  
Age and sex are the most important deter-
minants of breast cancer incidence
6
.  Breast 
cancer incidence is low in women before 40 
years of age, but then increases steeply. The 
mean age of developing breast cancer in 
Sweden is 63 years and approximately 10% 
of the breast cancer cases are diagnosed 
among women younger than 45 years of age
5
.  
Only 0.5% of all breast cancer cases are 
male
5
 .   
 
The aetiology of breast cancer is multifactori-
al and not fully known. Several risk factors 
have been identified in the development of 
the disease, although it is not clear why a 
breast cell mutates and becomes malignant. 
The association between hormonal activity 
and the risk of developing breast cancer has 
been studied extensively. Early menarche, 
late menopause, low parity and late child-
birth, as well as hormone replacement thera-
py with combined oestrogen and gestagen 
increase the risk
6, 10, 11
. This is also true of 
oral contraceptives, but to a more moderate 
degree
6
. Obesity and high intake of alcohol 
are lifestyle factors that increase the risk of 
breast cancer in post-menopausal women
6, 12, 
13
, while physical activity decreases the risk
14
.  
A breast with a dense mammography pattern, 
i.e. a breast rich in connective and epithelial 
tissue, increases the risk for breast cancer
15
, 
as does exposure to radiation at a young age
6
. 
 
The risk factors for developing an in situ 
breast cancer are largely the same as for inva-
sive breast cancer
16, 17
. Population-based stu-
dies that use family history data predict that 
5% of women with DCIS carry a mutation in 
the BRCA 1 or BRCA 2 genes
18
. The mean 
age of developing in situ breast cancer in 
Sweden is 59 years
19
. Women with in situ 
breast cancer have an increased risk of devel-
oping in situ or invasive breast cancer in the 
ipsi- or contralateral breast
20-30
.  Moreover 
women with in situ breast cancer, even after 
treatment, are at increased risk of subsequent 
invasive breast cancer compared to women in 
the general population
20, 22-28, 31-33
.  Several 
Helena Sackey 
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factors have been associated with invasive 
recurrences after in situ diagnosis, including 
patient characteristics 
23, 24, 27
, tumor characte-
ristics
23, 24, 34
 and treatment
23, 35, 36
.  
 
Familial aggregation of breast cancer has 
been observed all over the world. In  general, 
early onset and bilateral disease are two im-
portant features in these families 
37
. A Scan-
dinavian twin study has revealed that heredi-
tary factors are  important in 27% of all breast 
cancers
38
 and 5-10 % of the cases appear to 
be the results of autosomal dominant genes
39
. 
In 1994 and 1995, respectively, the two tu-
mour-suppressor genes BRCA 1 on chromo-
some 17 and BRCA 2 on chromosome 13 
were cloned.  Carrying a mutation in either of 
these suppressor genes entails a 50-80% life-
time risk of developing breast cancer 
40
, how-
ever, these mutations only account for 2-3% 
of all breast cancer cases
41, 42
. In the clinical 
setting, hereditary breast cancer is defined as 
≥ three cases of breast cancer in the same 
branch of the family, of which at least one 
occurs prior to age 50
42
. An aggregation that 
does not fulfill these criteria is called familial 
breast cancer
42
.  In population-based studies, 
a family history is defined as having one first 
degree family member with breast cancer. 
Two meta-analyses of familial risks for breast 
cancer presented the relative risks associated 
with having a first degree relative of breast 
cancer of 2.1 and 1.8, respectively
43, 44
.  There 
are statistical models for estimating the risk 
for individual patients and these are used in 
oncogenetic counselling
45
. Genetic testing, 
risk prediction and counselling are offered to 
women with an accumulation of breast and 
ovarian cancer in their families
9, 42
. 
 
 
Figure 1. Number of new invasive breast cancers in Sweden by year of diagnosis. 
 Cancer i siffror 2012. The National Board of Health and Welfare.
Background 
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Prognostic and treatment pre-
dictive factors  
Despite the increasing incidence during the 
last 30-40 years, there has been a slight de-
crease in mortality rates since the 1980s and 
today, approximately 87% survive five years 
after diagnosis
5
. This is partly due to earlier 
diagnosis through mammography screening 
programmes, multidisciplinary team confe-
rences, well established national guidelines, 
and high awareness among women together 
with more effective adjuvant treatment.  De-
spite this, one in four women diagnosed with 
breast cancer dies of the disease
5
. In Sweden, 
breast cancer accounts for approximately 3% 
of the total mortality among women, and 
around 1500 women a year die from the dis-
ease
5
.  
The mortality for women diagnosed with in 
situ breast cancer is considered to be at most 
only marginally increased, but remains less 
well characterized and with few exceptions, 
studies are often limited by short follow-up 
and non-population based designs
32, 46
 .  
The factors that traditionally have been as-
sociated with breast cancer recurrence and 
death are patient´s age, tumor stage accord-
ing to the Tumor-Node-Metastasis (TNM) 
classification and histological grade. Today, 
breast cancer characterisation has expanded 
and is also classified according to the ex-
pression of different receptors and biomark-
ers, which provide prognostic and/or predic-
tive information regarding therapy response. 
 
 
Age 
The mean age for being diagnosed with 
breast cancer in Sweden is 63 years and only 
5% of the breast cancers are diagnosed in 
women younger than 40 years of age
1
. Very 
young
47
 and very old
48
 women seem to have 
worse prognoses. Breast cancers in young 
women are more often oestrogen receptor 
(ER)-negative, of a higher histological grade 
and have a higher proliferation, which is as-
sociated with poor prognosis
49
. In older 
women, poor survival may be related to co-
morbidity or receiving adjuvant therapy less 
often than would be appropriate, given their 
tumour characteristics
48
. 
 
 
TNM classification 
The TNM classification system is based on 
tumour size and invasiveness (T), number of 
lymph node metastases (N) and the presence 
of distant metastases (M). The prognostic 
information obtained from the size of the tu-
mour is well established, only 10-20% of 
women with a tumour < 1 cm will have 
lymph node metastases compared with 50% 
of women with a tumour size > 2 cm
42
. 
 
This TNM classification is divided into four 
stages. Stage I means no nodal involvement 
(no tumour growth outside the breast) and the 
tumour is < 2cm. Stage II is a breast cancer > 
2-5 cm with no metastases or that the tumor 
is <5 cm with movable lymph node metastas-
es. Stage III includes cases with tumor spread 
to the skin of the breast or chest wall or 
fixed lymph node metastasis. In stage IV, 
there are distant metastases. In stage I, the 10-
year survival is 80-100%, and with a limited 
spread to the lymph nodes, stage II, the prog-
nosis is still good, at around 60-70%
42
. 
 
After the introduction of mammography 
screening the frequency of early breast cancer 
without lymph node metastases has increased 
and today about two thirds of all patients 
have no axillary metastases at diagnosis
42
. In 
addition to the traditionally used prognostic 
markers, biomarkers expressed by tumor cells 
are today more clinically relevant. In case of 
some biomarkers, like ER and human 
epidermal growth factor receptor 2 (HER2), 
they provide both prognostic and treatment 
predictive information. 
 
Helena Sackey 
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Histopathological classification and 
the Nottingham Histological Grade  
Breast cancer is not an entity but a collective 
name for malignancies in the breast tissue 
with different genetic background and prog-
nosis.  Roughly, there is invasive and in situ 
breast cancer and the classification according 
to the World Health Organisation (WHO) is 
based on the histological appearance of the 
cancer. 
 
Invasive breast cancer 
Invasive breast cancer is divided into six his-
tological groups and ductal and lobular inva-
sive breast cancer account for approxi-mately 
50-80% and 5-15%, respectively. Other types 
of rare invasive breast cancers are tubular 
carcinoma, medullary carcinoma, mucinous 
carcinoma, invasive cribriform, invasive pa-
pillary carcinoma and metaplastic breast can-
cer. Inflammatory breast cancer has symp-
toms including all the signs of inflammation, 
and the symptoms are caused by obstruction 
of the lymphatics
42
. 
 
Invasive breast cancer is further graded ac-
cording to the Nottingham Histological 
Grade, a three-grade scoring system for tu-
mour aggressiveness based on mitotic count, 
tubular formation and degree of nuclear aty-
pia. The score is a measure of how similar the 
tumour cell is to normal breast cell, i.e. the 
degree of differentiation. This grade is an 
independent prognostic factor with almost 
100% 5-year survival among grade 1 patients 
and 60% in grade 3 patients
42
. 
 
 
In situ breast cancer 
In situ breast cancer is by definition a cancer 
that respects the natural barrier, i.e. the basal 
membranes, and does not invade or infiltrate 
their surroundings. In situ breast cancer can 
be divided into ductal carcinoma in situ 
(DCIS) and lobular carcinoma in situ 
(LCIS)
42
. 
DCIS is a precursor lesion that has the 
potential to transform into an invasive 
cancer over a timespan that may be a few 
years or decades long. DCIS was rarely 
diagnosed before the introduction of national 
mammography screening programmes in the 
late 1990s and today, the majority of DCIS 
cases are screening detected, thus 
asymptomatic
19
.  DCIS that presents with 
clinical signs is more likely to be extensive 
or to have an invasive component
42
.   
The traditional system for classifying DCIS 
was based primarily on the architectural pat-
tern of the lesion and recognised five major 
subtypes: comedo, cribriform, micropapil-
lary, papillary, and solid
50
. The hallmark of 
the comedo pattern is the presence of promi-
nent necrosis in the involved spaces, which 
can be appreciated on macroscopic examina-
tion as cords of pasty material exuding from 
the cut surface of the specimen or readily 
expressed from involved ducts by palpation.  
Many of the involved spaces contain necrot-
ic cellular debris within their centres. This 
necrotic material frequently becomes calci-
fied, and these calcifications may be de-
tected mammographically
51
. 
At present, there is no universally accepted 
histopathological classification of DCIS. In 
Sweden, DCIS is graded according to 
Holland’s classification system52. This is 
based on cytonuclear differentiation and 
architectural differentiation (cellular polari-
sation).  The presence of nuclear necrosis is 
also included in this system and, all together, 
DCIS is divided into three subgroups
52
.  
LCIS is considered to be a marker of 
increased risk of an invasive cancer rather 
than a precursor 
42
. An incident finding of 
LCIS does not require treatment but 
warrants follow-up
9
. 
Bio- and proliferation markers 
Breast cancer is further classified according 
to the expression of different receptors. In 
1896, Beatson showed remarkable 
regression in some breast cancer patients 
with metastatic disease after oophorectomy. 
Background 
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In 1970, the ER was identified and the 
positive response to endocrine ablation 
could be explained
53
. ER activates 
transcription and is often up-regulated in 
tumour cells. ER is expressed in over three 
quarters of breast cancer patients and is 
associated with a better prognosis
42, 54
. 
The progesterone receptor is also often up-
regulated in tumor cells and is 
simultaneously expressed in >50% of the 
Erpositive  tumours
42
. The PR appears not to 
have any ER-independent mechanism of 
action. In a meta-analysis, no benefits of 
endocrine therapy in ER-negative, PR-
positive tumours were found
54
.  
HER2 is a tyrosine kinase receptor located 
on the cell membrane and was identified and 
reported to be amplified in women with 
breast cancer in the late 1980s
55
. 
Approximately 20% of all breast cancers 
express HER2
56, 57
 and it is strongly 
associated with increased disease recurrence 
and a poorer prognosis
58
. 
Ki67 is a proliferation marker expressed in 
the cell nucleus in all phases of the cell cycle 
except G0, with a maximal expression at 
mitosis
42
.  The exact function of Ki67 is not 
known, out high expression is associated 
with poor prognosis and blocking Ki67 
prevents cell proliferation
59
. All three 
receptors (ER, PR and HER2) and Ki67 can 
be assessed by immunohistochemistry
42
. 
 
 
Molecular subtypes 
Global gene expression profiling describes 
the activity or level of expression of a 
particular gene by counting the mRNA 
instead of the protein for which the gene 
encodes. At the beginning of the 21
st 
century, 
malignant breast tumours were analysed by 
hierarchical clustering and were shown to 
subdivide into five subgroups
60, 61
. These 
subgroups of tumours have revealed critical 
differences in response to treatment
62, 63
 and 
survival
60, 61
.  
 
The technique of gene expression profiling 
has been developed and commercial multi-
gene assays are available. These genetic 
techniques have, due to their high costs, led 
to surrogate molecular subtypes based on 
immunohistochemical analyses of the bio-
markers used in the clinical setting, i.e. ER, 
PR, HER2 and Ki67. The surrogate molecu-
lar subtypes recommended by the St. Gallen 
International Expert Consensus on the Pri-
mary Therapy of Early Breast Cancer 2013
64
 
are:  
 luminal A: ER+ and/or PR+, HER2- 
and Ki67low 
 luminal B: ER+ and/or PR-, HER2- 
and Ki67 high or low  ER+ and/or 
PR+, HER2- and Ki67 high      
 luminal HER2+: ER+ and/or PR+, 
HER2+ and any Ki67  
 HER2 type: ER-, PR- and HER2+ 
 triple negative: ER-, PR- and 
HER2- 
Helena Sackey 
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Diagnostics 
The diagnosis of breast cancer diagnosis is 
based on a triple diagnostic procedure with 
clinical examination of the breast and loco-
regional lymph nodes, mammography and/or 
ultrasound of the breast and cytological ex-
amination of cell sample obtained by fine-
needle aspiration or histopathological exami-
nation of core biopsy. Using this triple proce-
dure the sensitivity is very high, with less 
than 1% missed cases
65, 66
.  Mammography 
screening in Sweden started in 1986 and 
reached complete national coverage by 
1997
67
. According to Swedish guidelines all 
women between the ages 40 and 74 are of-
fered mammographic examination at regular 
intervals
68
. In Sweden, approximately 50% of 
all breast cancers are diagnosed by mammo-
graphy screening
19
. In comparison to clinical-
ly detected breast cancer, screening-detected 
breast cancers are smaller, more often node-
negative and in general have a lower histo-
logical grade and a better prognosis than clin-
ically-detected tumours
69, 70
. The benefits of 
mammography screening have been debated 
and opponents claim that the benefits are 
cancelled out by the risks of over- diagnosis 
and over- treatment
71
. Data from a Cochrane 
review suggested that screening reduces 
breast cancer mortality by 15% and that over 
diagnosis and over treatment runs at 30%
72
. 
An overview of the Swedish randomised tri-
als, show that the relative risk reduction in 
breast cancer mortality is approximately 
21%
73
. 
 
Ultrasound is a routinely used complement to 
mammography and has a higher sensitivity, 
especially in women with high density breasts 
74
. Magnetic resonance imaging (MRI) is rec-
ommended when screening women who are 
BRCA 1 and/or 2 carriers, as MRI is reported 
to have a higher sensitivity than other imag-
ing modalities
75
. 
 
Treatment 
Sweden has national and regional guidelines 
for the treatment of breast cancer and the 
primary treatment for the majority of patients 
is surgery
68, 76
. According to these guidelines, 
all breast cancer patients are to be discussed 
at pre- and postoperative multidisciplinary 
conferences. Surgery of the breast is currently 
performed either as a mastectomy or breast-
conserving surgery, where the tumour-
bearing part of the breast is removed. Since 
the 1990s, breast-conserving surgery has be-
come more common than mastectomy and 
today approximately 55% of all patients in 
Sweden receive breast-conserving surgery
19
. 
The decision regarding the surgery is based 
on tumour size in relation to the size of the 
breast, whether there are multiple cancer re-
gions in the breast and the patient’s own 
wishes. Prospective randomised trials, with 
long follow-up times, have not shown any 
differences in survival between breast-
conserving surgery, followed by radiotherapy 
of the breast and mastectomy
77-79
.  
 
 
History of breast cancer treatment 
The contemporary history of breast cancer 
surgery is strongly associated with the Amer-
ican surgeon William Halsted (1852-1922). 
In 1882 he performed the first radical mas-
tectomy at the John Hopkins Hospital
80
. The 
radical mastectomy comprised en-bloc extir-
pation of the breast gland, the pectoral major 
and minor muscles and extensive removal of 
axillary and adjacently located lymph nodes 
(exposing the subclavian vein and the brachi-
al plexus). This extensive procedure resulted 
in comparatively superior locoregional con-
trol and became the gold standard for breast 
cancer surgery for the next hundred years. 
However, the severe disfigurement created by 
the radical mastectomy also raised doubts as 
to whether such extensive surgery was neces-
sary. In 1948, Patey and Dyson described a 
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modification of the Halstedian operation and 
named it the ―modified radical mastectomy‖. 
Here, the pectoralis major muscle was spared, 
which significantly decreased postoperative 
morbidity
81
.  In the 1960s, Bernard Fisher 
revolutionised cancer treatment with the 
theory that breast cancer may be a systemic 
disease, the outcome of which would not 
merely depend upon the extent of locoregion-
al treatment
82
. With the advent of radiothera-
py in the1930s and 1940s, and the knowledge 
of the side effects of extensive surgery, alter-
native surgical procedures such as breast-
conserving surgery and mastectomy, with or 
without radiotherapy, and more limited axil-
lary dissection were introduced in clinical 
studies
77, 81, 83
. 
 
The application of oncoplastic surgery 
techniques further allows complete removal 
of the tumour with adequate surgical margins, 
and preserves the natural appearance of the 
breast
84
. In case of mastectomy, the loss of a 
breast might constitute a psychological trau-
ma for some women and a breast reconstruc-
tion can help to restore body image and im-
prove health-related quality of life (HRQOL) 
after mastectomy
85, 86
. 
 
Historically, DCIS was treated with mastec-
tomy, but since the 1980s, breast-conserving 
surgery for DCIS has been recommended 
whenever feasible. Mastectomy and breast-
conserving surgery for DCIS have not been 
compared in randomized trials.  However 
data from observational studies suggest that 
the rates of local or regional recurrence are 
significantly lower after mastectomy than 
after breast-conserving surgery, but no sig-
nificant differences in survival has been 
shown 
87-89
 . Mastectomy is still recom-
mended for women with multifocal DCIS 
and/or an unfavourable proportion between 
tumor size and breast volume. For these 
women immediatebreast reconstruction (IBR) 
may be an alternative in order to maintain a 
breast contour. 
 
 
Breast reconstruction  
Reconstruction of the breast can be per-
formed using an implant or autologous tissue, 
or a combination of both. In 1961, the first 
silicone implant was launched by Cronin and 
Gerow and, in 1963, the first implant was 
placed into a patient
90
. Becker further devel-
oped the tissue expander which came into 
frequent use in the 1990s. Since then, five 
generations of implants have been developed. 
The advances primarily include improvement 
of materials, design and contour.  
 
The choice of a reconstructive method is a 
multifactorial issue with many aspects to take 
into consideration, e.g. oncological safety, 
primary or delayed reconstruction, autolog-
ous tissue or implant, and the patient’s condi-
tion and preferences. The local expertise and 
competence in reconstructive surgery influ-
ences the choice of method. Breast recon-
structions were initially made mainly by plas-
tic surgeons as a delayed procedure. Howev-
er, the number of IBRs has increased in re-
cent years, and so has the number of breast 
surgeons performing the procedure.  
 
Any woman planned for mastectomy may be 
a candidate for IBR. Absolute contraindica-
tions are inflammatory cancer, growth in skin 
or thoracic wall, and relative contraindica-
tions are distant metastases, patients who are 
active smokers and/or obese, and those with 
co-morbidities and unrealistic expectations. 
Although the number of performed IBRs has 
increased in recent years, the proportion of 
breast cancer patients undergoing the proce-
dure in Sweden is only 6%
19
. 
 
 
Axillary surgery 
 
Axillary surgery is indicated in all patients 
with invasive breast cancer, and axillary 
lymph node status is an important prognostic 
factor for breast cancer recurrence and 
death
91, 92
. Axillary surgery is primarily a 
staging procedure to determine prognosis and 
decide upon the appropriate adjuvant thera-
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py
9
. However, it also protects against axillary 
recurrence and for some patients, it has a 
survival benefit
93-95
. The fewer the nodes that 
are removed the greater the likelihood of 
leaving involved nodes in the axillae, fol-
lowed by a higher risk of axillary 
recurrence
95
. However, the more axillary 
lymph nodes removed, the greater risk of arm 
morbidity
96
. The removal of ten lymph nodes 
has been suggested as reasonable compro-
mise
42
. Earlier detection of breast cancer by 
the introduction of mammography screening 
has resulted in an increasing number of pa-
tients with smaller tumors and node negative 
disease
69, 70
. For patients without axillary me-
tastases, axillary lymph node dissection 
(ALND) is of no value. ALND was the stan-
dard surgical procedure well into the 1990s, 
when it was replaced by the sentinel lymph 
node biopsy (SLNB), for those patients being 
clinically node-negative
97
.  
 
 
Sentinel lymph node biopsy 
The sentinel node is the first lymph node or 
group of lymph nodes draining a cancer. The 
term ―sentinel node‖ was first used in 1951 
by Gould et al, who, during a parotidectomy 
for a parotid cancer, noticed a normal looking 
lymph node at the junction of the anterior and 
posterior facial vein. The node was excised 
and sent for frozen section pathology and, 
surprisingly, was found to be a metastatic 
lymph node
98
. In 1977, Cabanas used the 
term sentinel node to describe a group of 
lymph nodes most likely to be the primary 
site for metastases in penile carcinoma. He 
suggested that these lymph nodes could be 
removed by limited surgery and examined to 
determine whether further lymph node dis-
section should be performed
99
. The injection 
of blue dye into the breast tissue was per-
formed by Turner-Warwick to demonstrate 
the lymphatic drainage of the breast in the 
late 1950s
100
. In 1993, the SLNB technique 
was described in breast cancer patients using 
Tc99m-sulphur colloid and gamma 
detector
101
. The following year, the first study 
in breast cancer patients using the blue dye 
method was published
102
.  Shortly thereafter a 
study using a combination of blue dye and 
isotope was published, which demonstrated 
improved detection rate
103
. In Sweden, the 
SLNB was introduced through nationwide 
studies before it become a clinical routine
97, 
104
. 
 
The sentinel node is identified by injecting a 
radioactive isotope intradermally, close to the 
tumour prior to the operation. Blue dye is 
injected in the same area when the patient is 
on the operating table. The blue dye and the 
isotope follow the lymphatic drainage of the 
area in the same way metastatic tumor cells 
are drained. A gamma probe is used to locate 
the sentinel node in the axillae and the dissec-
tion can start 5-10 minutes after the injection 
of the dye. The isotope and the blue dye help 
the surgeon to identify the affected lymph 
node or nodes by following a blue lymphatic 
tract and listening to the gamma-probe. The 
resected lymph node or nodes can be sent for 
immediate histopathological analysis. If me-
tastases are found, complementary ALND is 
performed.  
 
The major advantage of SLNB is that in the 
case of absence of sentinel node metastases, 
the rest of the axillae is left intact; which de-
creases the risk of postoperative arm morbidi-
ty. In a meta-analysis, the incidence of arm 
lymphoedema was about four times higher in 
women after ALND than it was in those who 
had SLNB
96
. Despite the less invasive nature 
of SLNB, studies have indicated that there is 
still a risk of arm morbidity such as limitation 
in movement of the shoulder, arm lymphoe-
dema and paraesthesia
105-108
. Another possi-
ble advantage is a more accurate staging, as 
the dye and isotope identifies the lymph node 
or nodes most likely to contain metastases, a 
lymph node that might have been left out dur-
ing ALND. The SLNB has been validated in 
several studies and has a high sensitivity
97, 104, 
109
. Furthermore, overall survival, disease-
free survival, and regional control appear to 
be equivalent between groups
110, 111
.
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Figure 2.  Sentinel lymph node biopsy.    Figure 3. The sentinel lymph node. 
With the kind permission of Jana de Boniface.   
 
 
The need for SLNB in patients with a preo-
perative diagnosis of DCIS is debated. There 
have been reports that question the need for 
SLNB in patients with pure DCIS due to the 
very low rate of axillary metastases
112-114
. 
However, in a meta-analysis, the overall es-
timate for the incidence of sentinel lymph 
node SLN metastases in patients with a preo-
perative diagnosis of DCIS was 7.4% 
115
. In 
clinical practice, SLNB is considered in 
patients with high risk DCIS (grade III, with 
palpable mass or large size on imaging), as 
well as in patients undergoing mastectomy 
after a prior breast-conserving surgery for 
DCIS. 
 
  
 
Radiotherapy 
Already in the latter part of the 19
th
 century, 
radiotherapy was given to breast cancer pa-
tients. Initially it was given mainly as pallia-
tion for advanced breast cancer cases, but 
from 1930 onwards radiotherapy was given 
as a complement after radical surgery
42
. Post-
operative radiotherapy is given in order to 
eradicate microscopic residual tumours and, 
to reduce loco-regional recurrence and, po-
tentially, improve overall survival. According 
to Swedish and International guidelines, radi-
otherapy to the breast or chest wall is recom-
mended for those patients treated with breast-
conserving surgery or after mastectomy for 
tumours >5cm, i.e. when the risk of local re-
currence is >20% within the next 10 years
9
. A 
meta-analysis reported that after breast-
conserving surgery, radiotherapy to the breast 
reduces the risk of recurrence by 50% and 
reduces breast cancer mortality by about a 
sixth 
116
.  
 
There is no world-wide consensus on the rad-
iation dose and fractions that are used after 
breast cancer surgery, and in Sweden there 
have been different regimes in different re-
gions.  Today, after breast-conserving sur-
gery, the national guidelines recommend ra-
diotherapy delivered as two opposed tangen-
tial fields in 25 fractions of 2 gray (Gy) up to 
a total dose of 50 Gy.  An additional booster 
dose of 16 Gy is given to patients ≤ 40  years 
of age at diagnosis 
9. Women with ≥4 axillary 
lymph node metastases receive radiotherapy 
both to loco-regional lymph nodes and to the 
chest wall after mastectomy. For breast tu-
mours < 5cm, in patients with 1-3 lymph 
node metastases, the benefits of loco-regional 
therapy of the axillae and supraclavicular area 
is uncertain
9
. According to present national 
guidelines radiotherapy should be considered 
in patients with 1-3 lymph node metastases, 
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in presence of lymphovascular invasion, age 
≤ 40 and histological grade III. Radiotherapy 
should also be considered if >20% of the ex-
amined lymph nodes have metastases.  
 
Four randomised clinical trials have shown 
that postoperative radiotherapy after breast-
conserving surgery for DCIS significantly 
reduces the risk of a ipsilateral DCIS or 
invasive recurrence by almost 50%
36, 117-119
. 
An overview from 2010 reported that radio-
therapy reduced the absolute 10-year risk of 
any ipsilateral breast event by 15%
120
. Older 
(>50 years) patients received greater benefit 
from radiotherapy than younger ones.  
 
Early side effects from radiotherapy includes 
erythema, fatigue, nausea and pneumonitis
42, 
121
. Years after radiotherapy, side effects such 
as arm lymphoedema, skin atrophy, pain, 
fibrosis of the lung, and ischemic heart 
disease can occur
42, 79, 122, 123
. Brachial plexus 
neuropathy with paralysis is a severe but un-
common side effect with the radiation dose 
and fractions that are used today
124
. 
 
 
Systemic therapy 
Adjuvant systemic therapy is given to elimi-
nate micro metastases remaining in any part 
of the body and includes endocrine therapy, 
chemotherapy and anti-HER2 therapy. 
 
Endocrine therapy 
The main source of oestrogen are the ovaries 
in premenopausal women, while in post-
menopausal women most of the body's 
oestrogen is synthesised from adrenal and 
ovarian androgens in the muscles, adipose 
tissue and liver. Approximately 70-80% of 
all breast cancer tumours are ER-positive
42
.  
The effects of oestrogen on the tumour can 
be inhibited either by blocking the ER with 
tamoxifen, by binding, blocking and increas-
ing the degradation of the ER by fulvestran, 
or by preventing the synthesis of oestrogen 
by aromatase inhibitors. Tamoxifen can be 
used for all ER- and/or PR-positive breast 
cancer regardless of menopausal status.  In a 
meta-analysis, ER- positive breast cancer 
patients treated with tamoxifen for about 
five years, experienced a reduction in breast 
cancer mortality of about a third throughout 
the first 15 years
54
. Prolonged treatment with 
tamoxifen for total of 10 years has been re-
ported to further reduce breast cancer death 
125
.  The most common side effects caused 
by tamoxifen are hot flushes, vaginal 
dryness, discharge, or irritation and 
decreased interest in sex
126, 127
. Other side 
effects that are rare but more severe include 
endometrial cancer and thromboembolic 
events
42, 127
.  
The effect of aromatase inhibitors is restricted 
to postmenopausal women as they work by 
inhibiting the action of the enzyme 
aromatase, which converts androgens into 
oestrogens in peripheral tissue and have no 
effect on the ovarian oestrogen production. 
Studies have shown a significantly reduced 
recurrence rate and mortality when compar-
ing aromatase inhibitors with tamoxifen in 
postmenopausal women with hormone-
sensitive breast cancer
128-130
. A recent meta-
analysis, however, revealed no significant 
decrease in mortality, yet an absolute reduced 
recurrence rate of 2.9% when comparing five 
years of treatment with tamoxifen versus 
aromatase inhibitors
131
. Side effects for 
aromatase inhibitors include osteoporosis, 
fractures, arthralgia and hyper-
cholesterolemia
127, 132
. 
 
In a randomised study, women treated with 
breast-conserving surgery and radiotherapy, 
tamoxifen reduced the likelihood of an 
ipsilateral breast cancer recurrence five 
years after surgery from 9 to 6%
133
. Today, 
tamoxifen is not routinely given to patients 
with DCIS. 
 
Chemotherapy 
Adjuvant chemotherapy was introduced in 
clinical trials in the 1950s and the first study 
reporting a significantly improved survival 
was published in 1968
82
. Bonadonna initiated 
the first randomised clinical trial comparing 
polychemotherapy versus no chemotherapy 
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in node-positive breast cancer patients and 
reported a decrease in recurrence rate
134
. 
Overall survival was also increased at 20-year 
follow-up
135
. The Early Breast Cancer Tria-
lists’ Collaborative Group (EBCTCG) was 
established in the early 1980s and the aim 
was to coordinate meta-analyses of all ran-
domised trials of adjuvant breast cancer 
treatment. The first meta-analysis was pre-
sented in 1988 and the latest in 2012, which 
reported that the 10-year risk of death from 
breast cancer can be reduced by a third for 
women treated with modern regimes with the 
addition of taxanes to athracyclines compared 
with women treated with no chemotherapy
136
. 
These results were independent of age, nodal 
status, tumour size, histological grade, ER 
status and Tamoxifen use. These meta-
analyses have provided the basis for modern 
chemotherapy and current guidelines recom-
mend chemotherapy to patients with axillary 
lymph node metastases. Node-negative pa-
tients with unfavourable tumour characteris-
tics such as large tumour size >1cm, high 
proliferation rate, ER-negative tumours, 
HER2 positivity and young age may also be 
recommended chemotherapy
9
. Chemotherapy 
for breast cancer has – like most chemothera-
py regimens – a number of side effects. It is 
important to even further tailor the adjuvant 
chemotherapy so only women who benefit 
from the therapy receive it, as it has been 
shown to have several side-effects and symp-
toms that negatively affect quality of life
137, 
138
. There is no role for chemotherapy in 
DCIS treatment 
51
. 
 
Monoclonal antibodies 
Trastuzumab is a monoclonal antibody 
directed against the tyrosine kinase receptor 
HER2. Over-expression of HER2 occurs in 
approximately 15% of breast cancers 
patients
57
 and is strongly associated with an  
increased risk of recurrence and a poorer 
prognosis
56, 58
. Adjuvant treatment with 
trastazumab reduces mortality by 30% and 
recurrences by 50%
139-141
. The most clinically 
significant side effect of trastuzumab is the 
risk of cardiac myocyte injury, leading to the 
development of congestive heart failure
56
. 
 
 
The lymphatic system and  
lymphoedema 
 
The lymphatic system  
Olof Rudbeck, a Swedish scientist published 
his theses De Cirkulatione Sanguinis in 1652 
and became the first to describe the function 
of the lymphatic system
142
.  The initial lymph 
vessels start blindly, are valveless, branch 
abundantly and are anastomose free. They 
consist of a single endothelial layer and 
communicate with larger vessels, the precol-
lectors, which in addition also contain an ac-
cessory membrane, a few smooth muscle 
cells and valves. Next, the lymph collectors 
consist of three layers (intimae, media and 
adventitia) corresponding with the layers in 
veins and arteries. They also contain valves. 
The smooth muscle cells in the collectors, 
together with valves, direct the lymph to-
wards the heart
143
. There are superficial, deep 
and visceral collectors. The later supply the 
inner organs, the superficial collectors merely 
follow the superficial veins and the deep 
lymphatic vessels are located beneath the 
muscle fascia and follow the main blood ves-
sels. The superficial and deep lymphatic sys-
tems are considered to be anatomically sepa-
rated from one another. Connections between 
them have, however,  been demonstrated es-
pecially under pathological conditions
144
. 
There are also lymphovenous communica-
tions, some of which function constantly 
whereas others do so only under pathological 
conditions
145
.  These connections could ena-
ble the transit of circulating tumor cells from 
one system to another
146
.  
On the way from the periphery to the central 
veins, the lymph passes at least one lymph 
node.  The presence of lymph nodes is the 
major difference between the blood and the 
lymphatic vessel
143
. The most frequent me-
tastatic location for breast cancer is in the 
axillary lymph nodes. There are three levels 
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of axillary lymph nodes in the axillae. Level 
I is the bottom level, below the lower edge 
of the pectoralis minor muscle.  Level II lies 
underneath the pectoralis minor muscle and 
Level III is between the pectoralis minor 
muscle and the lower border of the clavicle. 
The sentinel lymph node is usually found in       
level I
42
. The ipsilateral axillary lymph 
nodes receive more than 75% of the 
lymphatic drainage from the breast with the 
lymph nodes below the pectoralis minor 
muscle receiving it first. The internal 
mammary chain represents another 
important pathway for the lymph drainage 
from the breast. There are reports that the 
incidence of a positive sentinel lymph node 
in the internal mammary chain in up to 32% 
of cases, although solitary metastases here 
are very rare
109, 147
.  
 
 
Arm lymphoedema  
Lymphoedema is divided into primary and 
secondary lymphoedema. Primary lymphoe-
dema is caused by a disease or malformation 
in the lymphatic vessels, whereas a secondary 
lymphoedema is a result of disease or trauma 
in another organ
143
. Unlike oedema caused by 
heart failure, lymphoedema is rich in pro-
teins, which in the long-term has a negative 
effect on the tissue by stimulating the growth 
of fibrocytes
143
.  Arm lymphoedema is de-
fined as a chronic swelling of the upper limb 
caused by an impairment of lymph drainage. 
It is a well-recognised long-term complica-
tion related to breast and axillary surgery, 
radiotherapy and nodal status. Other factors 
such as recurrent infections may increase the 
incidence. It can also cause recurrent erysipe-
las, which increases the swelling even 
more
148, 149
.  
 
Arm lymphoedema in breast cancer patients 
was first described as a side effect of radical 
mastectomy by Halsted in 1921
150
. The de-
struction of lymphatic vessels, removal of 
lymph nodes and tissue scarring results in an 
incapacity for the remaining lymph vessels to 
remove the lymph. The vessels become di-
lated, overloaded and their valves incompe-
tent. This spreads distally until the most peri-
pheral lymph vessels become dilated, result-
ing in the accumulation of interstitial fluid, 
usually in the subcutaneous tissue
151
. At this 
stage the lymphoedema is soft and pitting 
oedema can be seen. In a parallel process, the 
mononuclear phagocyte system begins to lose 
its capacity to remove the proteins that accu-
mulate. These proteins are osmotically active 
and attract even more fluid to the area. In 
time, there will be an increase in the adipose 
tissue, due to an effect of the decrease in 
lymph circulation
152-154
. The mechanism for 
this is not yet fully understood. It is the in-
crease in adipose tissue that subsequently 
causes subcutaneous lymphoedema to be-
come firm and denser
155
. Later, the activation 
of fibrocytes increases the component of con-
nective tissue in chronic lymph oedema
143
. 
Due to increased breast cancer incidence and 
reduced mortality, more women will face the 
risk of developing lymphoedema. Arm lym-
phoedema can be severe and causes consider-
able psychological morbidity, pain, disability 
and impairs the activities of daily living
137, 156-
159
.  
 
The reported incidence of arm lymphoedema 
after breast cancer surgery varies widely, 
from 6 to 49%, and can occur weeks to years 
after surgery 
107, 159-164
. The true incidence is 
difficult to assess because of the varying cri-
teria used to define lymphoedema, differenc-
es in measuring the oedema and different fol-
low-up times across studies. ALND has pre-
viously been standard for staging the axillae 
in women with invasive breast cancer. How-
ever, it is associated with a number of side 
effects including lymphoedema, pain, numb-
ness and limited shoulder movements
156, 157, 
161, 165
. Despite the less invasive nature of 
SLNB, studies have indicated that there is 
still a risk for arm morbidity such as limita-
tion in movement of the shoulder, arm lym-
phoedema and paraesthesia
105-108, 166
. 
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Measurements  
Mainly for therapeutic reasons there have 
been attempts to classify arm lymphoedema. 
Several techniques, classified as internal and 
external, have been used to measure the dif-
ference in the involved arm compared with 
the non-operated side after breast cancer sur-
gery.   
The internal techniques are expensive, highly 
technology-based and include computed to-
mography, magnetic resonance imaging, ul-
trasound with and without Doppler flow, bio-
impedance spectroscopy and lymphoscinti-
graphic investigations
167, 168
.  
The external techniques involve clinical 
signs, measuring arm circumference or arm-
volume by using water displacement volume-
try, or they can be based on functional dis-
abilities or self-perceived symptoms
169, 170
. 
Water displacement volumetry offers a relia-
ble and objective method and is considered 
the gold standard for measuring arm lym-
phoedema
167, 169, 170
. The definition used by 
Stillwell is based on the volume of the oede-
ma in relation to the contralateral limb ex-
pressed as a percentage: insignificant (<10% 
difference), slight (10-20%), moderate (20-
40%), marked (40-80%) and severe 
(>80%)
171
. The lymphoedema can also be 
classified into clinical signs as proposed by 
the International Society of Lymphology; 
grade I is characterised by pits left after pres-
sure and is largely reduced or completely res-
tored after arm elevation. Grade II is charac-
terised by fibrosis and does not respond to 
either pressure or arm elevation
172
. 
 
 
Treatment  
In the initial phase of the lymphoedema there 
is only lymph in the oedema and it is reversi-
ble and more easily treated. The International 
Society of Lymphology and the Swedish 
guidelines recommend non-surgical treatment 
to prevent worsening of the lymphoedema 
and prevent increase in adipose tissue
172, 173
. 
Ideally, patients should be evaluated by a 
multidisciplinary rehabilitation team and be 
offered conservative treatment including in-
formation, skin treatment, standard elastic 
comprehension garments, exercise and a spe-
cific form of massage known as manual lym-
phatic drainage. This massage is thought to 
mobilise oedema fluid from the distal to 
proximal areas and from areas of stasis to 
healthy lymphatics. For patients with large 
lymphoedema, an intense period of treatment 
for 2-3 weeks is needed.  Compression thera-
py may also be provided with the use of 
compression pumps.  For patients who are 
not sufficiently responsive to nonsurgical 
treatment reconstructive microsurgery with 
lymphaticovenous anastomosis may be a 
therapy to consider
174-176
. However, it is only 
performed in some centres and the evidence 
is low. 
 
The above therapies work when the excess 
swelling consists of accumulated lymph but 
do not work when the excess volume is dom-
inated by adipose tissue 
177
. Chronic non-
pitting oedema can be removed by the use of 
liposuction. There are results that this can be  
done without further reduction in lymph 
transportation and that it has good long-term 
results
177-179
. However,  the use of a compres-
sion garment after liposuction is necessary to 
maintain the normalised arm volume
179
.  
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Patient-reported outcome  
measures 
 
HRQOL, the term for quality of life used in 
research and clinical practice, is limited to the 
quality of life related to a disease, and its 
symptoms and treatment
180
. Half a century 
ago, the WHO introduced this multidimen-
sional health concept by defining health as ―a 
state of complete physical, mental and social 
well-being, and not merely the absence of 
disease or infirmity‖181. Although there is no 
generally accepted definition of HRQOL, 
most definitions agree that HRQOL is a mul-
tidimensional concept including at least four 
dimensions: physical function, emotional 
function, cognitive and social function, as 
well as symptoms and problems related to the 
disease. It should preferably be estimated by 
the individual himself and is variable over 
time
180
. Several models of HRQOL have 
been presented, of which the model presented 
by Wilson and Cleary in 1995 is the most 
frequently used in published HRQOL 
studies
182, 183
. This model integrates biologi-
cal and psychosocial aspects of health out-
comes by linking measures of HRQOL to 
traditional clinical variables. Five core do-
mains are depicted in the scheme, including 
biological and physiological factors, symp-
tom status, functional status, general health, 
perceptions, and overall quality of life
182
. As 
stated above, HRQOL is a subjective experi-
ence and should preferably be reported by the 
patient. Studies have shown that there is poor 
correlation between patients’ and health pro-
fessionals’ evaluation of patients’ problems 
184
, as well as the experts versus the patients 
opinion on for example the outcome of a re-
constructive breast reconstruction
185, 186
. The 
U.S. Food and Drug Administration recently 
coined the umbrella term patient-reported 
outcome (PRO),which further emphasises the 
subjective nature of HRQOL
187
.  A PRO is 
any report coming directly from patients, 
without interpretation by physicians or others 
about how they function or feel in relation to 
their health condition, disease or its therapy. 
Thus, PRO is a broader term than HRQOL, 
encompassing the  effects of treatment, symp-
toms, side effects, perception of treatment 
and satisfaction with care
187
.  
There is a wide variety of different HRQOL 
questionnaires available. These can schemati-
cally be categorised into generic, disease-
specific, and aspects or domain-specific. Ge-
neric HRQOL questionnaires are intended for 
use across a wide range of populations, al-
lowing for the comparison of data across 
studies and against the general population. 
The most widely used is the Medical Out-
comes Study-36 item short form (SF-36). 
Disease-specific HRQOL-questionnaires 
cover issues that are relevant to certain 
groups of diseases, e.g. the Functional As-
sessment of Cancer Therapy-General (FACT-
G) and the European Organization for Re-
search and Treatment of Cancer Core Quality 
of Life Questionnaire (EORTC QLQ-C30), 
which is intended for cancer patients. These 
questionnaires can be complemented with 
modules for a specific cancer site and treat-
ment aspects e.g. the EORTC-BR23, in-
tended to assess breast cancer specific topics. 
 
Aspect- or domain-specific questionnaires 
address one specific domain of HRQOL in 
greater detail and include the Hospital Anxie-
ty and Depression Scale (HADS), the Body 
Image Scale (BIS), and the McGill Pain 
Questionnaire. 
 
 
Breast cancer and HRQOL 
Among the HRQOL studies in cancer pa-
tients, breast cancer has received most atten-
tion for several reasons. Firstly, the number 
of women with breast cancer is increasing. 
Secondly, the early detection and treatment of 
breast cancer has improved and survivors 
now live longer; thus studying HRQOL in 
this context is important. Thirdly, breast can-
cer affects women's identities and therefore 
studying the HRQOL is vital.  
There is a significant body of literature 
regarding HRQOL in breast cancer patients. 
Background 
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In summary, these studies report that the 
diagnosis and treatment, in particular 
chemotherapy and endocrine treatment, have 
a negative effect on patients' HRQOL
188-191
. 
The psychosocial impact of the type of pri-
mary surgery for breast cancer occurs largely 
in areas of body image and feelings of attrac-
tiveness, with women receiving breast con-
serving surgery experiencing the most posi-
tive outcome 
85, 192, 193
. Beyond the first years 
after diagnosis, a woman's quality of life is 
more likely influenced by her age or exposure 
to adjuvant therapy than by her breast cancer 
surgery.  
 
With this stated, the majority of "long-term 
survivors" after breast cancer report a good 
overall HRQOL, despite the fact that many  
patients have some specific problems such as 
arm morbidity and sexual problems
138, 194-198
. 
Comorbidity, lack of social support, financial 
problems, and previously having had 
adjuvant chemotherapy all appears to have 
negative impact on HRQOL
138, 198, 199
.   
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AIMS OF THE THESIS
 
 
 
 
 
The main aim of this thesis was to extend the knowledge on health-related quality of life 
and lymphoedema after breast cancer surgery and to evaluate the risk of future invasive 
disease following an in situ breast cancer diagnosis.  
 
 
The specific aims were: 
 
 
1. To investigate and compare long-term health-related quality of life, body image, and 
emotional reactions in women with ductal carcinoma in situ breast cancer treated with 
different surgical methods. 
 
2. To evaluate long-term risk of subsequent breast cancer and mortality in women diag-
nosed with in situ breast cancer. 
 
3. To evaluate the impact of family history on long-term risk of subsequent breast cancer 
and mortality among women diagnosed with in situ breast cancer.  
4. To compare arm lymphoedema after sentinel lymph node biopsy alone versus axillary 
lymph node dissection, both in node-negative and node-positive breast cancer patients.  
5. To examine the potential association between self-perceived symptoms of arm lym-
phoedema and objectively measured arm lymphoedema.  
6. To compare long-term health-related quality of life in patients undergoing sentinel 
lymph node biopsy alone versus axillary lymph node dissection, with or without axillary 
metastases.  
7. To assess the impact of objective arm lymphoedema and self-perceived symptoms of 
arm lymphoedema on health-related quality of life in patients with invasive breast can-
cer. 
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“Whenever a theory appears to you as the only possible one, take 
this as a sign that you have neither understood the theory nor the 
problem which it was intended to solve”. 
 
Karl Popper
Subjects and Methods 
33 
 
 
SUBJECTS AND METHODS
 
 
 
Data Sources 
 
The Regional Breast Cancer Register 
Stockholm- Gotland (Paper I) 
Since 1976, all new primary breast cancers in 
the Stockholm-Gotland Health Care Region 
have been reported to a central regional breast 
cancer registry
200
. The register holds informa-
tion on the individually unique national regis-
tration number, International Classification of 
Disease (ICD)-code, date of diagnosis, recep-
tor status, surgery, adjuvant treatment as well 
as data on locoregional and distant recur-
rences. 
 
 
The Plastic Surgery Register (Paper I) 
The register was initiated in 1990 to report on 
all immediate breast reconstructions per-
formed at the Department of Reconstructive 
and Plastic Surgery at Karolinska University 
Hospital. The register holds information on the 
individually unique national registration num-
ber, diagnosis, date of surgery and surgery 
performed. 
 
 
The Swedish National DCIS study 
(Paper I) 
The Swedish National DCIS study was a 
multicentre study that assessed the effect of 
postoperative radiotherapy after breast con-
serving surgery
36
. A total of 1046 women 
with screening-detected DCIS were rando-
mised to postoperative radiotherapy or not 
between 1987 and 1999. The primary end-
point was ipsilateral local recurrence.   
 
 
Multi-Generation Register (Paper II) 
The Multi-Generation Register (MGR) in-
cludes all Swedish residents born after 1931, 
who were alive in 1960, and all those born 
thereafter
201
. The Register was initiated in 
1961 from written records in church parishes 
and country registration offices. It contains 
links between children and parents through 
their individually unique national registration 
numbers. From 1961 to 2001 the complete-
ness of the MGR improved substantially and 
since 1991 it has been considered to be al-
most complete.  
 
 
Swedish Cancer Register (Paper II) 
The Swedish Cancer Register was established 
in 1958.  It is a nationwide, population-based 
register that contains information on virtually 
all diagnosed cancers in Sweden since 
1958
202
.  Reporting new cancer diagnoses is 
mandatory for all clinicians and pathologists. 
The register is considered complete for inva-
sive cancer
203-205
 and almost complete with 
regard to in situ breast cancer from 1980 on-
wards
204
.  All cancer diagnoses are registered 
according to ICD-code.   
 
 
The Swedish Causes of Death Regis-
ter (Paper II) 
The nation-wide Swedish Causes of Death 
Register was established in 1952. It provides 
information on date and cause of death, as 
well as the underlying and contributory caus-
es of death of all deceased Swedish residents. 
The completeness of the register is estimated 
to exceed 99%
206
. 
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The Total Population Register  
(Paper II) 
The Total Population Register records the 
vital life events of the inhabitants of 
Sweden
207
. The data is administered by the 
Swedish Tax Agency. The register spans 
several centuries of data and provides 
information on each citizen’s personal 
identity number, sex, births, marital status, 
address, country of birth, immigration, 
emigration, and date of death. 
 
 
Study Population 
 
Paper I 
All women who took part in the Swedish Na-
tional DCIS study
36
 between 1991 and 1999 
in the County of Stockholm were eligible. 
Furthermore, all women with DCIS who un-
derwent mastectomy and immediate breast 
reconstruction at Karolinska University Hos-
pital, Stockholm, during the same period, 
were asked to participate in the present study. 
Only women with DCIS proven by final his-
topathology, a total of 162 women, were in-
cluded in the study. Exclusion criteria were: 
Paget’s disease of the nipple, invasive breast 
cancer, lobular carcinoma in situ, ongoing 
tamoxifen treatment, and a history of present 
or previous malignancy (except basalioma 
and cervical cancer). Furthermore, women 
with dementia, severe brain damage, and 
without sufficient knowledge of the Swedish 
language were excluded, as were those with 
an invasive recurrence after primary DCIS 
surgery. Prior to inclusion, all data were con-
trolled against the Regional Breast Cancer 
Register to validate the DCIS diagnosis. 
 
 
Paper II  
Data from the Multi-Generation Register (in-
cluding more than 11 million individuals, 
from around three million families)
 
were 
combined with the Swedish Cancer Register, 
the Cause of Death Register, and the Total 
Population Register.  Family history of breast 
cancer was defined as having at least one 
first-degree relative diagnosed with invasive 
breast cancer at any point in time.  Our final 
study population consisted of 8111 women in 
the Swedish Multi-Generation Register diag-
nosed with primary diagnosis of in situ breast 
cancer between January 1
st 
1980 and January 
1
st 
2005. 
 
 
Papers III and IV 
The study cohort consisted of 557 women 
with invasive breast cancer undergoing breast 
cancer surgery in four centres in Sweden be-
tween 1999 and 2004.  Difficulty in under-
standing the Swedish language, bilateral 
breast cancer, clinically fixed axillary metas-
tases, neoadjuvant treatment and previous 
surgery or radiation therapy to either axillae 
were exclusion criteria.  
 
 
Methods 
 
Treatment (Studies I, III and IV) 
Patients were treated according to the prevail-
ing national and regional guidelines; breast-
conserving surgery was performed as a sector 
resection as previously defined
208
.  For wom-
en who had mastectomy and immediate 
breast reconstruction, the reconstructive me-
thod was implant based with an expander 
prostheses (Paper I). All axillary lymph node 
dissections (ALND) included level I and II. 
The sentinel nodes were identified by the 
combined dye and isotope mapping-
technique
102
. Experienced breast surgeons or 
trainees under supervision performed the op-
erations.  
 
Radiotherapy was administered with tangen-
tial fields with 2 Gy daily 25 times up to 50 
Gy to the breast after breast-conserving sur-
gery and to the chest wall after mastectomy 
for tumours over 5 cm.  Postoperative adju-
vant chemotherapy and/or endocrine treat-
Subjects and Methods 
35 
 
ment was recommended according to the 
Swedish guidelines depending on the pa-
tient’s age, hormone receptor status, lymph 
node status, Elston grade, HER2 status and 
comorbidity
9
. 
 
Arm volume (Papers III and IV) 
Arm volume was measured using the water 
displacement technique
170, 209
, which is con-
sidered a reliable and valid tool for estimating 
arm volume after breast cancer surgery
210
. A 
nurse, trained in the procedure, measured 
both arms repeatedly and the difference in ml 
between the arms was recorded. This differ-
ence defined the increase in arm volume and 
was followed over time and compared be-
tween study groups.   
 
 
 
Figure 4. Arm volume measurement. 
With the kind permission of Håkan Brorson and the 
patient. 
 
 
Questionnaires 
 
The Hospital Anxiety and Depression 
(HAD) scale (Paper I) 
The HAD scale consists of 14 items, seven 
assessing anxiety and seven depression
211
. 
The possible sum score of each scale ranges 
from 0 to 21, with each item scored from 0 to 
3 points. High summated scores represent 
high levels of problems. Cut-off points for 
each of the scales are: < 8 (within normal 
range), 8-10 (possible clinical case), and ≥11 
(clinical case). The HAD scale is considered 
a reliable and valid instrument for the as-
sessment of anxiety and depression in somat-
ic, psychiatric, and primary care patients, as 
well as in the general population
212
. The 
Swedish version has been validated in breast 
cancer patients against diary recordings
213
.  
 
 
The Body Image Scale (BIS) (Paper I)  
The BIS was designed for the assessment of 
body image in cancer patients
214
. It consists 
of 10 items concerning the impact of surgery 
on self-consciousness, physical and sexual 
attractiveness, femininity, satisfaction with 
body and scars, body integrity, and avoidance 
behaviour. The BIS items are scored from 0 
(not at all) to 3 (very much). A high score 
represents problems with body image. The 
BIS scale has a high reliability and good clin-
ical validity
214
. No formal validation or relia-
bility testing of the Swedish version has been 
performed. The translation into Swedish was 
performed by a group of five professionals 
(three nurses, one sociologist, and one psy-
chologist) at the Department of Oncology, 
Karolinska University Hospital. 
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Figure 5. The measurement model of SF-36 questionnaire. Adapted from Ware et al. 1992.  
 
The Swedish SF-36 Health Survey  
(Papers I and IV)
The Swedish SF-36 Health Survey (SF-36) is 
used to asses health-related quality of life 
(HRQOL). It is a standardised questionnaire 
that has been widely used in international 
studies. The Swedish version has been vali-
dated, and normative data for Swedish wom-
en are available
215, 216
. The SF-36 consists of 
36 items constituting eight domains: physical 
functioning (PF), role limitations as a result 
of physical problems (RP), bodily pain (BP), 
general health perception (GH), vitality (VT), 
social functioning (SF), role limitation due to 
emotional problems (RE), and mental health 
(MH). The first three domains (PF, RF, and 
BP) measure physical well-being and the last 
three (SF, RE, and MH) relate to emotional 
well-being. A high score on the subscales 
signifies a higher level of function and 
HRQOL.  
Self-perceived symptoms of lymphoedema 
(Paper III and IV) 
At the time of the start of the study there was 
no existing validated instrument for assess-
ment of symptoms after axillary surgery. 
Therefore, a questionnaire was designed by a 
group of breast surgeons, a physiotherapist 
specialized in arm lymphoedema treatment, a 
psychologist, and an anaesthetist specialising 
in pain management. The final questionnaire 
format was determined after using a pilot 
questionnaire in consultation with breast can-
cer patients. The questionnaire consists of 
eight questions: four regarding early signs of 
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lymphatic insufficiency (does your operated 
arm feel heavy, tired, sore or tense ?) and four 
regarding arm lymphoedema (are your fin-
gers, hand, arm or axillae/breast/chest wall 
swollen?). The items scores were, 0 (never), 1 
(sometimes) and 2 (always).  
 
 
Statistical Analysis 
 
Paper I 
The scores derived from the SF-36 question-
naire were linearly transformed into a 0-100 
scale according to the SF-36 manual
216
. The 
results were compared with normative data 
from an age-matched reference group consist-
ing of 920 women from the general Swedish 
population. The mean HAD subscale values 
were compared between groups, as well as 
proportions of patients in each clinical stage, 
as suggested by the original authors
211
. Stu-
dent’s t-test was used to evaluate differences 
between the study sample and normative data 
(SF-36). ANOVA repeated measurement was 
used to evaluate differences between the three 
study groups on HAD subscales and SF-36 
subscales. Chi-2 test was used for categorical 
data (HAD and BIS). Differences between 
groups were considered statistically signifi-
cant when p < 0.01. Statistical analyses were 
done using StatView version 4.5 (SAS Insti-
tute, Cary, NC, USA).  
 
 
Paper II 
The standardised incidence ratios (SIRs), i.e., 
the ratio of the observed to the expected 
number of breast cancers (ipsi-or contralater-
al invasive or contralateral in situ breast can-
cer), standardised by age and calendar period, 
were used as a measure of relative risk, and 
were stratified by family history of breast 
cancer.  All women were followed from the 
date of their first in situ breast cancer diagno-
sis until a subsequent breast cancer event, 
emigration, death, or end of follow-up, whi-
chever came first. The expected number of 
subsequent breast cancer events was calcu-
lated as the product of the person-years ac-
cumulated by women with in situ breast can-
cer by the age and calendar period-specific 
incidence of unilateral in situ/invasive breast 
cancer of the general population in the Swe-
dish Multi-Generation Register.  
 
Excess additive risks (EARs), i.e. the differ-
ence between the observed number of subse-
quent invasive breast cancers and the ex-
pected number in the general population in 
the Swedish Multi-Generation register, were 
used as a measure of absolute risk for subse-
quent invasive cancer.  
 
The standardised mortality ratio (SMR), i.e. 
the ratio of the observed to the expected 
number of deaths, standardised by age and 
calendar period, was used as a measure of 
relative mortality. The expected number of 
deaths was calculated from the general popu-
lation in the Swedish Multi-Generation regis-
ter.  For overall SMRs, subjects were fol-
lowed from the date of the first in situ breast 
cancer diagnosis until date of emigration, 
death, or end of follow-up, whichever came 
first. All data preparation and analysis were 
done using the SAS statistical package, ver-
sion 8.2 or higher (SAS Institute Inc., Cary, 
NC, USA).  
Helena Sackey 
38 
 
Paper III  
A mixed model with first order autoregres-
sive correlation structure was used to com-
pare the mean arm-volume difference be-
tween the three study groups over time. In the 
unadjusted model, the study group, years af-
ter surgery and their interaction term were 
included. In the adjusted model, body mass 
index (BMI) at surgery, age at surgery, preo-
perative difference in arm volume, surgery on 
the dominant side, body mass index change 
from the preoperative value, and radiotherapy 
to breast and lymph nodes were included. A 
mixed model was also used to evaluate arm-
volume differences with self-perceived symp-
toms of lymphoedema. 
 
Logistic regression for repeated measure-
ments by generalized estimating equations 
(GEE), with an exchangeable correlation 
structure was used to analyze differences in 
self-perceived symptoms of lymphoedema 
between groups, years after surgery and their 
interaction. In the adjusted model, age at sur-
gery, BMI at surgery, and BMI change from 
the pre-operative value were also included. 
The same type of GEE model and analysis 
strategy was applied for self-perceived early 
signs of lymphatic insufficiency.  
 
The unpaired t-test was used to compare con-
tinuous patient characteristics or, when ap-
propriate, the Mann-Whitney U-test. A chi-2 
test, or when appropriate, the Fisher’s exact 
test, was used for categorical variables. A p-
value less than 0.05 was regarded as statisti-
cally significant. All analyses were done us-
ing SPSS version 17 (SPSS Inc., Chicago, IL, 
USA) except GEE models where STATA 
release 11 (StataCorp. College Station, TX, 
USA) was used. 
 
 
Paper IV 
The scores derived from the SF-36 question-
naire were linearly transformed into a 0-100 
scale according to the SF-36 manual
216
. Ex-
pected mean scale scores were calculated by 
using age-specific normative data from the 
Swedish population and the indirect standar-
disation technique
215
. Linear regression mod-
els were used to estimate the effect of surgery 
on the SF-36 scales at the three-year assess-
ment. In the unadjusted models, surgery was 
the only variable included, whereas in the 
adjusted models, age, radiotherapy, chemo-
therapy, hormonal treatment and baseline 
(preoperative) SF-36 were included as well as 
surgery.  Reported p-values refer to F-tests. 
 
Lymphoedema was considered evident if the 
arm-volume difference (AVD) was >10%. 
Agreement between AVD and self-perceived 
symptoms of lymphoedema (SPS) was esti-
mated using the kappa statistic. Bootstrap 
was used to obtain the 99% confidence inter-
val. 
 
The risk of SPS at three-years was modelled 
by generalised linear models with log link 
and binomial distribution. Both unadjusted 
and adjusted (age, BMI, operation on domi-
nant side, radiotherapy to the axillae and 
preoperative difference in arm volume) ef-
fects of surgery (with sentinel lymph node 
biopsy (SLNB) as the reference category) 
were estimated, and were presented as risk 
ratios together with 99% confidence intervals 
and p-values from Wald tests.  
 
A chi-2 test or, when appropriate Fisher’s 
exact test was used to compare differences 
between the three study groups in categorical 
variables. The Kruskal-Wallis test was used 
to compare differences in continuous va-
riables. A p-value less than 0.05 was regarded 
as statistically significant. All analyses were 
done with STATA release 11 (StataCorpCo-
lege Station, TX, USA)  
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Table 1. Overview of Subjects and Methods. 
 
 
 
 
 
  
Paper I 
 
Paper II 
 
Paper III 
 
Paper IV 
 
Study De-
sign 
Cohort study 
Population-based co-
hort study 
Cohort study 
Data 
Sources 
1.The Plastic Surgery 
Register ,Karolinska 
University Hospital             
 
2.The Swedish Nation-
al DCIS study 
3. Stockholm Regional 
Oncological Cancer 
Centre Register  
1.The Multi-Generation 
Register 
2.The Swedish Cancer 
Register3.The Swedish 
Causes of Death Regis-
ter 
4.The Total Population 
Register 
 
Study Popu-
lation 
 
 
 
Women in Stockholm 
County in the Swedish 
National DCIS study 
and all women with 
DCIS who underwent 
mastectomy and IBR at 
Karolinska University 
Hospital            N=162 
All women in the Mul-
ti-Generation Register 
with first in situ breast 
cancer diagnosed   
 
N=8111 
Women operated for invasive breast cancer 
in four hospitals in Sweden 
 
 
                                                                                       
N=557 
 
Inclusion 
period 
1991-1999 1980-2004 1999-2004 
 
Follow-up 
1991 -2007 1980-2004 1999-2007 
Exposure/ 
Intervention 
Breast conserving sur-
gery  with or without 
radiotherapy, or mas-
tectomy and immediate 
breast reconstruction 
In situ breast cancer 
Family history for 
breast cancer 
Axillary surgery with/ without axillary 
metastases 
Outcome 
HRQOL assessed with 
SF-36, HAD  BIS 
Second breast cancer 
(invasive/in situ) 
 Mortality 
Arm lymphoedema 
Self-perceived symp-
toms  
HRQOL           
assessed  with  
SF-36 
 
Main  
statistical 
methods 
Student’s t-test ANO-
VA, Chi-2 test 
SIR, SMR, EAR,  life-
table method 
Linear mixed model           
Logistic regression by 
generalised estimating 
equations (GEE) 
Kappa statistics         
Generalised linear  
models, Linear 
regression models 
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"Just living is not enough," said the butterfly, "one must have   sun-
shine, freedom and a little flower." 
 
Hans Christian Andersen
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RESULTS AND DISCUSSION
 
 
 
Paper I 
 
In total, 162 women were included in the 
study and 131 (81%) responded to the ques-
tionnaires. The number of patients and rea-
sons for attrition are presented in Figure 6. 
The median age was 58.5 years (range 40-77) 
for women treated with mastectomy and im-
mediate breast reconstruction (IBR), 65.0 
years (range 55-83) for those treated with 
sector resection alone, and 64.0 years (range 
48-89) for women treated with sector resec-
tion and postoperative radiotherapy (RT). The 
mean time from surgery to completion of 
questionnaires was 7.0 years (SD 2.4) in the 
mastectomy and IBR group, 9.8 years (SD 
2.8) in the sector resection and postoperative 
RT group and 9.9 years (SD 2.7) in the sector 
resection alone group. 
 
 
Health-related quality of life (HRQOL) 
Overall, women in all three study groups ap-
peared to have a satisfactory HRQOL in the 
long term, similar to women in the general 
population. These findings are consistent with 
three other studies of long-term HRQOL 
among women with DCIS
217-219
. Women who 
underwent mastectomy and IBR scored high-
er on physical functioning and bodily pain 
than the other two study groups and also 
when compared with their age-adjusted norm 
groups (Table2). These findings, that women 
who underwent mastectomy and IBR re-
ported better physical functioning and less 
bodily pain than the other two study groups, 
and their age-adjusted norm groups, was not 
expected. It might be explained by a response 
shift, which is an adaptation process that pa-
tients with a disease undergo to accommodate 
their illness
220
. It is therefore possible that the 
more extensive surgical procedures and, 
probably, the more prolonged rehabilitation 
period that these women experienced resulted 
in a response shift with respect to bodily pain 
and physical functioning.  
 
The addition of postoperative radiotherapy to 
breast-conserving therapy did not appear to 
have negative impact on HRQOL in the long 
term.  
 
 
Figure 6. Number of patients and reasons for attrition. 
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Table 2.  Mean values for the SF-36 subscales for the three study groups and their age-adjusted 
norm values 
 
 
Anxiety and depression 
No statistically significant differences be-
tween the study groups were found for the 
mean scores on the HAD anxiety or depres-
sion subscales, nor for the proportions of pa-
tients scoring in the clinical category on the 
subscale. Our results show however, a trend 
towards increased levels of anxiety in the 
mastectomy and IBR group compared with 
the two other study groups. The mean anxiety 
score was 6.24 (SD 5.00) in the mastectomy 
and IBR group, and 3.76 (SD 3.25) and 4.41 
(4.22) in the sector resection alone group and 
sector resection and RT group, respectively 
(p-value=0.02). In addition, women in the 
mastectomy and IBR group also scored statis-
tically significantly lower than the other two 
study groups on the mental health subscales 
of the SF-36, although there were no statisti-
cally significant differences with their age-
adjusted norm group. It was expected that 
mastectomy and IBR, a treatment implying a 
lower risk of recurrence, would result in less 
anxiety than the two other treatment options. 
This hypothesis was not supported in this 
study, nor in an American study showing that 
the perception of risk of recurrence did not 
diminish in women with DCIS who under-
went mastectomy
221
.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
A Dutch study found that women with DCIS 
had comparable perceptions of the risk of 
recurrence and breast cancer death to women 
with invasive breast cancer, despite their bet-
ter prognosis
217
. We speculate that these 
trends, with increased anxiety and lower 
mental health, might reflect the more exten-
sive and longer treatment that mastectomy 
and IBR implies when compared with sector 
resection alone or followed by RT, and that 
these women may have become more aware 
of and affected by their disease.  
 
 
Body image 
Overall, statistically significant differences 
between the three study groups were found 
for six of the items (self-consciousness, feel-
ing less physically attractive, feeling less fe-
minine, feeling less sexually attractive, being 
dissatisfied with body, being dissatisfied with 
scars) with larger proportions of women in 
the mastectomy and IBR group reporting 
problems. To our knowledge, this is the first 
study comparing different surgical treatments 
with respect to long-term body image among 
women with DCIS. Three previous studies on 
long-term postoperative body image among 
women with invasive breast cancer reported a 
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more favourable body image among women 
treated with breast-conserving surgery than 
those treated with mastectomy alone
85, 192, 193
. 
Contradictory results have been found in stu-
dies that address whether mastectomy with 
reconstruction results in a better long-term 
body image than mastectomy alone
85, 196, 222
. 
In addition, one long-term follow-up study 
showed no differences in body image be-
tween women treated with sector resection 
and mastectomy with reconstruction
223
. It is 
important to consider that sector resection 
was not an option for most women in the 
mastectomy and IBR group and that the al-
ternative, mastectomy alone, is not 
represented in this study. Given that mastect-
omy and IBR is the surgical option that pro-
vides a superior esthetical result, emphasis on 
preoperative information about expected 
postoperative changes in body image may 
have improved these results.  
 
 
Methodological considerations, 
strengths and limitations 
This study has a number of limitations. No 
preoperative data on our study variables were 
collected and, therefore, it was not possible to 
ascertain differences in the studied variables 
before surgery. No women treated with mas-
tectomy alone were included and better body 
image might have been expected with IBR 
than without. Potential confounders in this 
study are age, tamoxifen treatment, invasive 
breast cancer or other malignancies and com-
orbidity. All patients with tamoxifen treat-
ment or an invasive cancer were excluded, 
but no adjustment for age was performed in 
the analysis, which is a limitation. The results 
on the SF-36 subscales are, however, com-
pared with age-adjusted norm data, which 
minimises the influence of age on these re-
sults. 
 
To our knowledge, there is no previous study 
evaluating long-term HRQOL and body im-
age in women with DCIS treated with differ-
ent surgical methods, including mastectomy 
with IBR and sector resection with or without 
radiotherapy. The assessments of the expo-
sures were thoroughly reviewed through 
medical records and the patients filled in the 
questionnaires in present time, which mini-
mises the risk for information and recall bias. 
The response rate to the questionnaires was 
81%, which is high considering the long pe-
riod between surgery and follow-up. Standar-
dised questionnaires employed in many pre-
vious studies were used. A threat to all stu-
dies that include multiple testing is the occur-
rence of a false positive finding reaching the 
level of statistical significance, i.e. a type I 
error. To reduce this risk, differences between 
groups were considered statistically signifi-
cant when p < 0.01. 
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Paper II 
Over a follow-up period of 71 458 person-
years, 825 (10.2%) women developed 886 
subsequent breast events (118 contralateral in 
situ and 768 ipsi- or contralateral invasive 
breast cancers). The average time from first 
in situ breast cancer diagnosis to a second 
breast event was overall 5.6 years +/- 4.6 
years. 
 
 
Second breast cancers in women di-
agnosed with in situ breast cancer  
Among women diagnosed with in situ breast 
cancer, the cumulative 10- and 20-year risk 
for a subsequent contra- or ipsilateral inva-
sive cancer was approximately 10 and 18% 
respectively, while the cumulative 10- and 
20-year risk for a subsequent contralateral in 
situ breast cancer was 1 and 2% respectively 
(Figure 7). 
 
The risk of a subsequent ipsi- or contralateral 
invasive breast cancer was increased more 
than fourfold [SIR 4.55 (95% CI 4.23- 4.88)] 
among women with in situ breast cancer 
compared with women in the general popula-
tion. The risk for a contralateral in situ breast 
cancer was increased almost sixteenfold [SIR 
15.98 (95% CI, 13.23-19.14)]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 7. Cumulative incidence of second breast event among women diagnosed with in situ breast 
cancer, stratified by types of subsequent breast events.  
 
 
Results and Discussion 
45 
 
 
Risk stratified by family history 
The proportion of subsequent breast events 
was similar in women with and without a 
family history (11.3%, n=97 versus 10.0%, 
n=728). In women with a positive family his-
tory, the risk for a contralateral invasive 
breast cancer was more than four times high-
er compared with women in the general 
population, and almost 50% higher compared 
with women with no family history of breast 
cancer (Table. 3). This observed increased 
risk is approximately twice as high as the risk 
of breast cancer that women with a positive 
family history without a previous breast can-
cer face. Two meta-analyses of familiar risks 
for breast cancer presented the relative risk 
associated with having a first degree relative 
of breast cancer to 2.1 and 1.8, respectively
44, 
224
. The observed diluted additional risk in 
women with a family history, i.e. only a 50 % 
increased risk for a contralateral invasive 
cancer, was lower than expected. We specu-
late that women with a positive family history 
were likely more prone to choose mastecto-
my, which would reduce the risk for an ipsi-
lateral cancer in these women. Additional 
stratification into one, two or even three af-
fected first-degree members to better quantify 
the hereditary component may have allowed 
a deeper understanding of these results.  
 
The reduced risk may also be a reflection of 
heterogeneity of the in situ breast cancer phe-
notype. Several studies have shown that the 
molecular profile of the primary invasive 
breast cancer can predict the risk of 
recurrence, metastatic behaviour and 
survival
225-227
. Much less attention has 
focused on the subtypes of in situ breast 
cancer. A population-based study from 
Sweden failed to demonstrate a prognostic 
value for the surrogate molecular subtyping 
of DCIS using the St. Gallen criteria
228
. 
Theoretically, it should be possible to identify 
an in situ expression profile that predicts a 
high probability of progression to the 
invasive form of the disease. We do not know 
however, if any of these subtypes occur to a 
greater degree in women with familial breast 
cancer. 
 
 
1background rate of in situ breast cancer was divided by 2.2includes ipsilateral, contralateral and missing side.   
3background rate of invasive breast cancer was divided by 2. *Reference group is No Family History. IRR has been adjusted for 
age and year of first diagnosis of in situ and time since first diagnosis. 
 
Table 3. SIR of second breast event after diagnosis of first in situ breast cancer and its 95% CI, by 
type of second breast event and family history.  
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Risk stratified by age 
Regardless of family history, women under 
forty years of age at diagnosis had a signifi-
cantly higher risk of subsequent invasive 
breast cancer compared with women above 
forty years, SIR 8.54 (95% CI 6.07-11.67) 
and 4.44 (95% CI 4.12-4.77) respectively (p-
value <0.001). These young women would 
experience an excess absolute risk (EAR) 
ranging from about eight events per 1000 
person-years to as high as 15 events per 1000 
person-years depending on family history. 
This absolute excess risk decreased with old-
er age only for women with a positive family 
history. In contrast, women with a family 
history of breast cancer had the highest EAR, 
with women under 40 years of age carrying 
the greatest EAR (154.10 per 10000 person-
years; 95% CI 77.14-266.30), compared with 
women older than 40 years at diagnosis 
(105.72 per 10000 person-years; 95% CI 
78.88-136.82). This suggests that both rela-
tive and absolute risks are higher with young-
er age of onset of in situ disease in women 
with a positive family history. Given that a 
younger woman with both a high risk of a 
subsequent event as well as a longer life ex-
pectancy, which translates to a higher cumu-
lative risk, mastectomy may be considered 
for this patient population. 
 
 
Risk stratified by calendar year 
Women with in situ breast cancer with no 
family history experienced an increasing risk 
of subsequent invasive cancer during the 
study period, SIR 3.09 (95% CI 2.42-3.89) in 
1980-1984, versus SIR 5.05 (95% CI 3.88-
6.46) in 2000-2004 (p-trend <0.001). In con-
trast, women with a family history expe-
rienced no such increased risk for a subse-
quent invasive breast cancer over the study 
period. 
 
The increased relative risk of subsequent in-
vasive breast cancer by almost 60% from 
1980-84 to 2000-04, exclusively in women 
with no family history, may be related to a 
combination of screening and treatment pat-
terns. During the study period, nationwide 
mammography screening was introduced, and 
had achieved complete national coverage by 
1997
67
. With increasing mammography 
screening, and subsequently, a larger number 
of detected smaller lesions–the majority of 
which are non-palpable–the use of breast-
conserving surgery has become the norm 
since 1990 onwards
68
. In comparison with 
mastectomy, breast-conserving surgery poses 
an increased risk of both local recurrence and 
new ipsilateral primary cancers
42
. In contrast, 
women with a positive family history had no 
increased risk during the study period and we 
speculate that these women, who had rela-
tives with breast cancer, were more prone to 
choose mastectomy.  
 
Risk stratified by time since diagnosis 
Regardless of family history, the risk of sub-
sequent invasive cancer during the first five 
years after the first in situ breast cancer was 
increased more than fivefold compared with 
the general population (SIR 5.20; 95% CI 
4.71-5.74). In women with no family history 
there was a significant decline in both the 
relative and absolute risk over time, but this 
was not observed in women with a family 
history. However, it remains that 15 years 
after the first in situ breast cancer diagnosis, 
the overall risk of an invasive breast cancer 
was almost three times higher than for wom-
en in the general population. This indicates 
that women diagnosed with in situ breast 
cancer have a lifelong increased risk, which 
needs to be taken into account when planning 
their follow-up.  
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*one subject has both ipsilateral and contralateral invasive breast cancer, that is why total is 6+5=11> 10. 1  includes ipsilateral, 
contralateral and missing side 
 
Table 4. SMR of second breast event after diagnosis of first in situ breast cancer, by type of second 
breast event and family history.  
 
Mortality after in situ breast cancer  
The overall risk of death in women with in 
situ breast cancer was significantly increased, 
by 30% compared to the general population, 
but highly dependent on the occurrence of a 
second invasive breast cancer event. Women, 
who did not develop a second invasive event 
following in situ breast cancer, had a similar 
mortality to the background population [SMR 
1.01(95% CI 0.95-1.08)]. In contrast, women 
who were diagnosed with a second invasive 
event had a twice as high mortality rate com-
pared with women in the general population 
[SMR 2.06 (95% CI 1.72-2.44)], with no sig-
nificant differences between women with and 
without a family history of breast cancer (Ta-
ble 4).   
 
Given that deaths were rare at younger ages 
we compared mortality among women above 
and below 50 years of age. Women below the 
age of 50 at the first in situ breast cancer di-
agnosis and who were diagnosed with a 
second invasive cancer had significantly 
higher mortality compared with women over 
50 years at diagnosis, (SMR 8.03; 95% CI 
5.38-11.54 versus SMR 1.70; 95% CI 1.39-
2.06).  
 
Young age at onset was an important predic-
tor of death for women with in situ disease 
due to an increased risk of second invasive 
cancers and thus a substantially higher mor-
tality. This should be taken into account when 
planning their treatment and follow-up.  
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Methodological considerations, 
strengths and limitations 
This study has some limitations. We have no 
treatment data nor have we distinguished be-
tween ductal carcinoma in situ breast cancer 
and lobular carcinoma in situ breast cancer.  
With this stated, a previous Swedish case-
control study has shown that the risk of a 
subsequent invasive breast cancer was equal 
after lobular and ductal carcinoma in situ 
breast cancer
34
. Due to regional differences in 
how to report second ipsilateral in situ breast 
cancer, such events were not included in the 
study. 
 
Strengths of the current study include the 
population-based design, its large sample size 
and complete follow-up. The information 
regarding family history is unlikely to be sub-
jected to any bias since it is not dependent on 
personal reporting but is collected by the tax 
authorities. In addition, the reporting of can-
cers to the Cancer Register is mandatory and 
the register is considered almost complete for 
invasive breast cancer
203-205
. Since 1980 it has 
also been of a very high reliability with re-
gards to in situ breast cancer
204
, which makes 
the risk of information bias unlikely. To the 
best of our knowledge, this is the largest 
study yet carried out to assess the impact of a 
positive family history of breast cancer on 
risk and mortality after in situ breast cancer.  
 
 
Papers III and IV 
Of the original 516 women who were operat-
ed in the axillae, 420 (81.4%) had a preopera-
tive and at least one postoperative measure-
ment of the difference in arm-volume; 96 
were non-attenders. The study groups were 
defined by the axillary procedure performed 
and the presence of axillary metastases: 1) 
sentinel lymph node biopsy (SLNB) alone 
(N=140), 2) axillary lymph node dissection 
(ALND) in patients without axillary metas-
tases (N=125) and 3) ALND in patients with 
axillary metastases (N=155). In the third 
study group we included patients with ALND 
performed due to preoperatively known axil-
lary metastases, as well as those with ALND 
performed after a positive SLNB. Clinical 
characteristics according to study group are 
shown in Table 5. No differences were seen 
between attenders and non-attenders in the 
three groups, except in the node-positive 
ALND group, where chemotherapy was giv-
en less frequently and more mastectomies 
were performed among non-attenders (data 
not shown).  
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1 Comparison between SLNB vs node negative ALND. Unpaired t-test for test of age at operation and chi-2 test for all other 
tests.2 Comparison between SLNB vs node positive ALND. Unpaired t-test for test of age at operation and chi-2 test for all other 
tests.  
 
Table 5. Description of patient characteristics and treatment. All patients have at least one postop-
erative measurement of arm-volume.  
 
 
Lymphoedema after axillary surgery  
In paper III, the adjusted mean arm-volume 
difference, three years after surgery, was 61 
ml (95% CI 10 to 113) in the node-negative 
ALND group and 61 ml (95 % CI 6 to 116) in 
the node-positive ALND group, both signifi-
cantly higher than the SLNB group (Table 6). 
Among women operated with SLNB alone 
there was no increase in postoperative mean 
arm-volume difference over time, while both 
ALND groups showed a statistically signifi-
cant increase (Figure 8).  
In paper IV, a dichotomous definition of arm 
lymphoedema was used, commonly used in 
the literature, i.e. the proportion of women 
having ≥10 % increase in arm volume differ-
ence. By this definition, we found that 5% in 
the SLNB group, compared with 13% and 
24% in the node-negative and node- positive 
ALNB groups, respectively, had an arm lym-
phoedema (p<0.001). There are two possible 
reasons for the lack of an increase in mean 
arm-volume difference over time even though 
5% in the SLNB group had a ≥10% increase 
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in arm- volume difference. There was a great 
variance in measured arm-volume and a wide 
range of harvested lymph nodes even in the 
SLNB group. Thus, some patients in this 
group had more than just the sentinel lymph 
nodes harvested. 
 
 
 
 
 
Figure 8. Mean arm-volume difference be-
tween operated and non-operated side over 
time 
 
 In a recent meta-analysis the overall inci-
dence for lymphoedema, when restricted to 
data from prospective studies, was 21.4% 
(14.9-29.8)
96
. The incidence was around four 
times higher in women who had ALND than 
it was among those having SLNB, 19.9% and 
5.6%, respectively. Although this pooled es-
timate was from studies with many different 
definitions of arm lymphoedema, our results 
are in line with previous studies and today 
around one fifth of all women diagnosed with 
breast cancer are  expected to develop arm 
lymphoedema
96
.  
 
Previous studies have shown that the majority 
of patients will develop arm-lymphoedema 
within the first two to three years after diag-
nosis
96, 163
. Our follow-up time in Papers III 
and IV was three years and the adjusted mean 
arm-volume difference three years after sur-
gery was 61 ml in both the node-negative and 
the node-positive group. However, the unad-
justed mean-arm volume difference was 67 
ml (95% CI 15,120) in the node-negative 
ALND group and 96ml (95%CI 45, 147) in 
the node positive group, which probably re-
flects the late effects of radiotherapy.  
 
 
 
1Adjusted for operation on dominant side, age at operation, BMI at operation and BMI change from preop, radiotherapy to the 
breast and radiotherapy to the axillae. 
Table 6. Mixed model with arm-volume difference between operated and non-operated side as 
outcome variable, comparison between time periods, n=420. 
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Self-perceived symptoms of arm lym-
phoedema 
It may take up to several years, before a lym-
phoedema develops; the water displacement 
technique therefore has little sensitivity in the 
preclinical setting. Bioimpedance spectrosco-
py has been shown to be sensitive to detect 
early extracellular fluid changes and can the-
reby be used in early diagnosis of lymphoe-
dema
229
. Self-report methods are an alterna-
tive way of capturing early signs of lymphoe-
dema which were also used in Papers III and 
IV in addition to the water displacement 
technique. The proportion of women report-
ing early signs of lymphoedema (does your 
operated arm feel heavy, tired, sore or 
tense?), one year after surgery, was 36% in 
the SLNB group, and 56% and 74% in the 
node-negative and node-positive ALND 
groups, respectively. Both ALND groups had 
a significantly higher risk compared with 
women in the SLNB group, adjusted odds 
ratio 2.2(95% CI 1.3-3.9) and 4.7(95% CI 
2.7-8.3), respectively. The differences  
remained statistically significant two and 
three years after surgery.  
 
Two years after surgery there was a positive 
correlation between greater mean arm-
volume difference and self-perceived arm 
lymphoedema which remained after three 
years. As shown in previous studies, using 
self-reported symptoms as a diagnostic indi-
cator of lymphoedema has its limitations, 
because many symptoms that are associated 
with lymphoedema are also common after 
breast cancer surgery in women without lym-
phoedema
230, 231
.   
 
In study IV, we defined arm lymphoedema as 
≥10% increase in arm volume difference and 
there was no statistically significant agree-
ment between self-perceived and objectively 
measured arm lymphoedema one and three 
years after surgery; kappa 0.05(95% CI -0.01-
0.12) and 0.10 (95% CI 0.02-0.18). These 
results indicate that it might not be those 
women with the most severe lymphoedema 
who report self-perceived symptoms of lym-
phoedema. 
Figure 9. Proportion of women in the three study groups reporting self-perceived symptoms of 
arm lymphoedema  
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The poor agreement between patient percep-
tions and objective measures has also been 
reported in two other studies
231, 232
. One of 
these studies suggested that factors other 
than limb enlargement, such as sensory 
nerve injury, may play a significant role as 
patients with numbness were more likely to 
report self-perceived arm lymphoedema
231
.  
Even if women treated with SLNB have a 
limited increase in mean arm-volume differ-
ence and fewer self-perceived symptoms of 
lymphoedema, as many as 20% report self 
perceived symptoms of arm lymphoedema 
and 5% experience ≥10% increase in arm-
volume difference. This emphasizes the im-
portance of performing SLNB strictly on pa-
tients who can benefit from the staging re-
sults. 
 
Today, there is an ongoing discussion wheth-
er ALND in sentinel node positive breast 
cancer is necessary. Further studies are 
needed to answer the question if ALND in 
sentinel node positive cases could be omitted, 
without effect on survival or local control
233, 
234
. However, if only considering the risk for 
arm lymphoedema, our study supports the 
trend to omit ALND in patients with positive 
sentinel node. 
 
 
Based on342 patients with HRQoL data. Observed scores in dark gray and expected in light gray. In black 99% CI for the ob-
served scores 
 
Figure 10. SF-36 assessment at 3 years.  
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HRQOL after axillary surgery  
Three years after surgery, the overall mean-
score for all study groups was statistically 
significantly higher for the bodily pain do-
main when compared with their age-specific 
norm-group (Figure 10).  No other statistical-
ly significant differences were found between 
the study groups and their respective age-
specific norm groups.  
In the unadjusted model, one year after sur-
gery, the score for physical role functioning 
was statistically significantly lower in the 
node positive ALND group compared with 
the two other study groups; mean score 51 
compared with 69 and 64, respectively 
(p=0.001). Patients in this group more often 
received chemotherapy, a well-known risk 
factor for poorer HRQOL
137, 190, 191, 235
. No 
other statistically significant differences were 
seen between the three study groups. 
 
In a recent published study from France, 
with a follow-up time of six years no 
statistically significant differences appeared 
in the HRQOL scores for global health 
between patients treated for ALND and 
SLNB
236
. However, on the scores for arm 
symptoms women treated with SLNB 
reported fewer symptoms than women 
treated with ALND. In addition, patients 
reporting arm lymphoedema had affected  
arm dimension subscores on HRQOL
236
.  
The SF-36 questionnaire used in our study is 
generic and it is possible that if we had used 
a disease- or aspect specific questionnaire 
we would have found an impact on surgery 
on certain domains on HRQOL. Our study 
indicates that after a few years treatment has 
less impact on the overall HRQOL, as 
women with breast cancer have the same 
HRQOL as the background population. Fig-
ure 11 shows the SF-36 profiles grouped by 
correlation between objective and subjective 
arm lymphoedema three years after surgery. 
Women with an objective lymphoedema but 
reporting no self-perceived symptoms of 
lymphoedema, reported the highest levels of 
HRQOL. On the other hand, women with no 
objective lymphoedema, but reporting self-
perceived symptoms of lymphoedema 
scored the lowest HRQOL.  
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Figure 12. The SF-36 profiles grouped by correlation between objective and subjective arm lym-
phoedema three years after surgery 
 
It has been shown in a few studies that spe-
cific arm symptoms, such as reduced 
shoulder abduction and pain – related  or 
unrelated to  arm lymphoedema – are  more 
associated with poor HRQOL outcomes than 
the arm swelling per se
237-239
. We speculate 
that women reporting symptoms of arm 
lymphoedema might associate other diffuse 
symptoms after surgery such as numbness, 
paraesthesia and wound pain as a sign of 
lymphoedema, and, in line with previous 
studies
237-239
, report lower levels of HRQOL. 
For the clinician, this is an important find-
ing, as it indicates that it is as important to 
focus on arm symptoms and pain, as it is to 
treat arm lymphoedema in order to help 
these patients. Another explanation might be 
that, three years after surgery, other factors 
such as personality and ability to cope with 
problems, have a greater impact on the 
HRQOL than the symptoms and disease it-
self. 
Methodological considerations, 
strengths and limitations 
Papers III and IV are based on the same pros-
pectively follow cohort. Regarding self-
perceived arm lymphoedema, one limitation 
is that baseline data were not available for 
these items and that the arm symptoms ques-
tionnaire was not validated.  The question-
naire was, however, constructed by a group 
of breast care professionals and piloted in a 
group of breast cancer patients before use in 
the present study. 
Another limitation is that no power analysis 
was carried out. There is therefore a potential 
risk for type II error, i.e. that the study is too 
small to reveal potential between group dif-
ferences. 
The strengths of this study are that it is pros-
pective, with assessments of both objective 
and subjective lymphoedema at multiple time 
points, and was performed at four large-
volume university-affiliated hospitals and 
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with a long follow up time. The HRQOL 
questionnaire is validated. In addition, we 
were able to include node-negative patients, 
treated with ALND in the study in order to 
evaluate the impact of surgery per se on arm 
lymphoedema. 
 
 
 
 
 
 
 
 
 
. 
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CONCLUSIONS
 
 
 
 
 
 
1. Women treated for DCIS have a satisfactory long-term health-related quality of life. The 
addition of radiotherapy to breast-conserving surgery does not seem to have any nega-
tive impact on health-related quality of life in the long-term. However, body image ap-
pears to be affected in women treated with mastectomy and immediate breast recon-
struction.  
2. Young women diagnosed with their first in situ breast cancer have both a higher risk for 
a future invasive breast cancer and higher mortality than their older counterparts,  which 
should be taken into account when planning their treatment and follow-up  
3. Among women with in situ breast cancer, a positive family history increases the risk  
only for a contralateral invasive breast cancer. 
4. Sentinel lymph node biopsy is associated with a minimal risk of increased arm volume 
and few self-perceived symptoms of arm lymphoedema, significantly less than after 
axillary lymph node dissection, regardless of lymph node status. Yet, 20% percent of 
women report symptoms of arm lymphoedema after sentinel lymph node biopsy, which 
emphasizes the importance of performing axillary surgery strictly on patients who can 
benefit from the staging results.  
5. Three years after surgery there is a weak correlation between mean arm volume differ-
ence and self-perceived symptoms of arm lymphoedema.  
6. Women treated for invasive breast cancer have a satisfactory long-term health-related 
quality of life.  
7. Women reporting self-perceived arm lymphoedema, regardless of objective lymphoe-
dema or not, scored lower on all eight SF-36 domains than those who did not, indicating 
that more attention should be given to the subjective reports of symptoms in order to 
better help these women.
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FUTURE PERSPECTIVES
 
 
In situ breast cancer 
Young women diagnosed with their first in 
situ breast cancer have both a higher risk for a 
future invasive breast cancer and a higher 
mortality than their older counterparts. In 
addition, they have less effect of post-
operative radiotherapy
240, 241
Paper II in this 
thesis, further indicates that the risk of a 
second invasive event after previous in situ 
diagnosis increased when breast-conserving 
surgery became more common in Sweden 
than mastectomies. Taken together, these 
facts indicate that mastectomy, with or with-
out primary reconstruction, might be consi-
dered for young patients with in situ breast 
cancer, in order to prevent an invasive breast 
recurrence. To answer the question – whether 
the type of surgery, i.e. breast conserving 
surgery versus mastectomy affects survival – 
we  plan to study the incidence of second in-
vasive and in situ and mortality in regard to 
surgical treatment in women diagnosed with 
in situ in the Stockholm-Gotland Region 
from 1980-2012.  
 
A subgroup of women with in situ breast 
cancer is most likely over-treated, and thus 
neither benefits from extensive surgery nor 
adjuvant treatment. Theoretically, it should 
be possible to identify an in situ expression 
profile predicting a low probability of an 
invasive cancer recurrence. A population-
based study from Sweden, however, failed to 
demonstrate a prognostic value for the 
surrogate molecular subtyping of DCIS using 
the St. Gallen criteria 
228
. It would also be of 
interest to analyse whether any of such 
hypothetical subtypes are more common in 
women with familial breast cancer. 
Arm lymphoedema 
Women treated with SLNB develop signifi-
cantly less arm lymphoedema and report 
fewer self-perceived symptoms of lymphoe-
dema than women treated with ALND, re-
gardless of nodal status.  In Paper II we ob-
served a trend towards a continued increase 
in arm lymphoedema in the node-positive 
ALND group when compared with the node-
negative group. It would be of interest to 
conduct a long-term follow-up 10 years after 
surgery in order to study whether this trend 
continues; this would indicate that the side 
effects of radiotherapy occur later and con-
tinue to increase for a longer period than the 
side effects of surgery. 
 
 
Patient-reported outcome 
Women treated for in situ and invasive  breast 
cancer overall appeared to have a satisfactory 
long-term HRQOL, similar to women in the 
general population. Women with self-
perceived symptoms of lymphoedema, re-
gardless of its objective measurable confir-
mation, scored lower on all HRQOL domains 
than women without symptoms. Thus, there 
might be other arm symptoms not analysed in 
this study that have an impact on HRQOL. It 
would therefore be of interest to study the 
impact of pain, numbness and reduced shoul-
der mobility on HRQOL.  
 
The concept of sense of coherence (SOC) 
was put forward by Aaron Antonovsky in 
1979 to explain why some people become ill 
under stress and while others stay healthy
242
. 
A high SOC was suggested to mirror success-
ful coping with stressors, thereby increasing 
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resilience. In our arm-lymphoedema study, 
the SOC-scale was used preoperatively and 
one year postoperatively. We aim to study 
correlations between preoperatively SOC 
scores, and HRQOL three years after surgery 
in order to investigate if the SOC-scale can be 
used as a predictive tool to identify women 
with risk for decreased long-term HRQOL. 
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